Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020 - PowerPoint PPT Presentation

About This Presentation
Title:

Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020

Description:

The acute lymphocytic leukemia therapeutics market was valued at $1.96 billion in 2010 and is expected to reach $3.88 billion by 2020, at a CAGR of 5.21% between 2015 and 2020. The market was dominated by Hyper-CVAD regimen in 2010. However, in 2020, the market is expected to be equally dominated by Hyper-CVAD and Linker regimen. The chemotherapy drug regimens were dominated by Hyper-CVAD regimen sales, totaling $1.8 billion and linker regimen sales totaling $1.13 billion sales in acute lymphocytic leukemia market. – PowerPoint PPT presentation

Number of Views:183
Slides: 6
Provided by: david765
Category:

less

Transcript and Presenter's Notes

Title: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020


1

Markets and Markets
Acute Lymphocytic Leukemia Therapeutics Market (
2020)
http//www.marketsandmarkets.com/Market-Reports/
acute-lymphocytic-leukemia-therapeutics-market-518
.html
2
INTRODUCTION
  • The market research report Marketsandmarkets
    adds a new report Acute Lymphocytic Leukemia
    Therapeutics Market (Pipeline Forecast Market
    Forecast in G8 Countries) (2010 - 2020) has
    been published by MarketsandMarkets. According to
    this report studies The acute lymphocytic
    leukemia therapeutics market was valued at 1.96
    billion in 2010 and is expected to reach 3.88
    billion by 2020, at a CAGR of 5.21 between 2015
    and 2020
  • Browse gtgt
  • Browse market data tables and in-depth TOC on
    Acute Lymphocytic Leukemia Therapeutics Market
  • Request to Download Free PDF Brochure _at_


3
Scope of Report
  • This research report categorizes the market in G8
    countries into the following segments
  • Acute Lymphocytic Leukemia Therapeutics Market,
    by Drug
  • Existing Regimens/Drugs
  • Hyper-CVAD Regimen
  • CALGB 8811 Regimen
  • Linker Regimen
  • Nucleoside Metabolic Inhibitors (Clolar and
    Nelarabine)
  • Oncaspar
  • Pipeline Drugs (Phase III)
  • Graspa
  • Marqibo
  • Inotuzumab Ozogamicin

4
Acute Lymphocytic Leukemia Therapeutics Market
5
About Marketsandmarkets MarketsandMarkets is a
global market research and consulting company
based in the U.S. We publish strategically
analyzed market research reports and serve as a
business intelligence partner to Fortune 500
companies across the world. MarketsandMarkets
also provides multi-client reports, company
profiles, databases, and custom research
services. They cover thirteen industry verticals,
including advanced materials, automotives and
transportation, banking and financial services,
biotechnology, chemicals, consumer goods, energy
and power, food and beverages, industrial
automation, medical devices, pharmaceuticals,
semiconductor and electronics, and
telecommunications and IT. We at
MarketsandMarkets are inspired to help our
clients grow by providing apt business insight
with our huge market intelligence repository.

Get in touch with us at 1-888-6006-441 or send
email to sales_at_marketsandmarkets.com with your
contact details and questions if any query.
Write a Comment
User Comments (0)
About PowerShow.com